Notícias e Atividades da Immune-Onc Therapeutics
Executivos
Veja o organograma con seus 13 executivos principais
Biografias mais buscadas da Immune-Onc Therapeutics
- Charlene Liao, Director, President and Chief Executive Officer
- Barbara Klencke, Director
- Jack Donahue, Director
Recentes movimentos de executivos em Immune-Onc Therapeutics
- Paolo Fundaro, ingressou na Companhia como Director (Notícia publicada em 21 de março de 2025).
- Mona Flores, ingressou na Companhia como Director (Notícia publicada em 21 de março de 2025).
Criar um alerta
para seguir os movimentos de executivos da Immune-Onc Therapeutics.
Biotecnologia
Immune-Onc Therapeutics possui 2.339 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Biogen (Estados Unidos).
Popular M&A news in Biotecnologia
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publicado em 30 de abril de 2025)..
- Deepull acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 29 de abril de 2025).
- Biolinq acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 23 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Immune-Onc Therapeutics
- Here are some recent breakthroughs by women-led life sciences companies in the Bay Area - San Francisco Business Times
- Here are six major breakthroughs achieved by Bay Area women-led biotechs - San Francisco Business Times
- Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting — Immune-Onc Therapeutics
- Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting — Immune-Onc Therapeutics
- Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting — Immune-Onc Therapeutics
- News — Immune-Onc Therapeutics
- LLS TAP announces five new investments supporting next generation immunotherapies | Leukemia and Lymphoma Society
- Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting — Immune-Onc Therapeutics
- Press Release — Immune-Onc Therapeutics
- LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies | Leukemia and Lymphoma Society
- View more press releases Close
Redes sociais sobre Immune-Onc Therapeutics
- Immune-Onc Therapeutics na Wikipedia, Google News e Yahoo Finance
- Immune-Onc Therapeutics na LinkedIn, Twitter e YouTube
